BR0115514A - Composto, composição farmacêutica, método de tratar ou melhorar condições ou doenças proliferativas, e, uso de um composto - Google Patents

Composto, composição farmacêutica, método de tratar ou melhorar condições ou doenças proliferativas, e, uso de um composto

Info

Publication number
BR0115514A
BR0115514A BR0115514-8A BR0115514A BR0115514A BR 0115514 A BR0115514 A BR 0115514A BR 0115514 A BR0115514 A BR 0115514A BR 0115514 A BR0115514 A BR 0115514A
Authority
BR
Brazil
Prior art keywords
optionally substituted
branched
cyclic
halogen
cyano
Prior art date
Application number
BR0115514-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Ernst Torndal Binderup
Pernill-Julia Vig Hjarnaa
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of BR0115514A publication Critical patent/BR0115514A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0115514-8A 2000-11-21 2001-11-14 Composto, composição farmacêutica, método de tratar ou melhorar condições ou doenças proliferativas, e, uso de um composto BR0115514A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25207800P 2000-11-21 2000-11-21
PCT/DK2001/000750 WO2002042265A2 (en) 2000-11-21 2001-11-14 Cyanoguanidine prodrugs

Publications (1)

Publication Number Publication Date
BR0115514A true BR0115514A (pt) 2003-12-30

Family

ID=22954502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115514-8A BR0115514A (pt) 2000-11-21 2001-11-14 Composto, composição farmacêutica, método de tratar ou melhorar condições ou doenças proliferativas, e, uso de um composto

Country Status (16)

Country Link
US (1) US6525077B2 (cg-RX-API-DMAC7.html)
EP (2) EP1339686B1 (cg-RX-API-DMAC7.html)
JP (1) JP4521157B2 (cg-RX-API-DMAC7.html)
KR (1) KR100871577B1 (cg-RX-API-DMAC7.html)
CN (1) CN100368401C (cg-RX-API-DMAC7.html)
AU (3) AU1494702A (cg-RX-API-DMAC7.html)
BR (1) BR0115514A (cg-RX-API-DMAC7.html)
CA (1) CA2426601C (cg-RX-API-DMAC7.html)
CZ (1) CZ305764B6 (cg-RX-API-DMAC7.html)
ES (2) ES2549260T3 (cg-RX-API-DMAC7.html)
HU (1) HU230544B1 (cg-RX-API-DMAC7.html)
IL (2) IL155483A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004394A (cg-RX-API-DMAC7.html)
PL (1) PL224371B1 (cg-RX-API-DMAC7.html)
RU (1) RU2312858C2 (cg-RX-API-DMAC7.html)
WO (2) WO2002042265A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
PL228742B1 (pl) * 2002-05-17 2018-05-30 Leo Pharma As Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
WO2003097602A1 (en) * 2002-05-17 2003-11-27 Leo Pharma A/S Cyanoguanidine produgs
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004089925A1 (en) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
US8053446B2 (en) 2004-12-22 2011-11-08 Leo Pharma A/S Cyanoguanidine compounds
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
EP2197443A4 (en) * 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8101606B2 (en) 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
CN102186822A (zh) 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
WO2010088842A1 (zh) 2009-02-06 2010-08-12 天津和美生物技术有限公司 含有吡啶基氰基胍的药物组合物及其制备和应用
EP2453883A1 (en) 2009-07-17 2012-05-23 Topo Target A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
US9224007B2 (en) * 2009-09-15 2015-12-29 International Business Machines Corporation Search engine with privacy protection
US9600134B2 (en) 2009-12-29 2017-03-21 International Business Machines Corporation Selecting portions of computer-accessible documents for post-selection processing
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US9195853B2 (en) 2012-01-15 2015-11-24 International Business Machines Corporation Automated document redaction
WO2013188813A2 (en) * 2012-06-15 2013-12-19 The Regents Of The University Of California Novel therapeutics for brain cancer
SG11201408770RA (en) * 2012-06-27 2015-01-29 Alzheimer S Inst Of America Inc Compounds and therapeutic uses thereof
EP2903979B1 (en) 2012-10-04 2020-08-19 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
US9892278B2 (en) 2012-11-14 2018-02-13 International Business Machines Corporation Focused personal identifying information redaction
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
EA039121B1 (ru) 2015-02-27 2021-12-07 Куртана Фармасьютикалс, Инк. ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
WO2018199174A1 (ja) * 2017-04-25 2018-11-01 生化学工業株式会社 第3級アミン化合物又はイミン化合物-ポリマーコンジュゲートとその製造方法
EP3590927A1 (en) * 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479951A4 (en) * 1989-06-26 1992-12-09 The Research Foundation Of State University Of New York Bis-acyloxymethyl derivatives
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds

Also Published As

Publication number Publication date
JP4521157B2 (ja) 2010-08-11
ES2549260T3 (es) 2015-10-26
HU230544B1 (hu) 2016-11-28
WO2002042276A1 (en) 2002-05-30
PL362864A1 (en) 2004-11-02
US6525077B2 (en) 2003-02-25
HUP0400564A3 (en) 2008-03-28
IL155483A (en) 2010-12-30
EP1339686B1 (en) 2015-09-16
MXPA03004394A (es) 2004-04-20
KR20030051861A (ko) 2003-06-25
EP2894149A1 (en) 2015-07-15
ES2643083T3 (es) 2017-11-21
US20020165201A1 (en) 2002-11-07
PL224371B1 (pl) 2016-12-30
WO2002042265A2 (en) 2002-05-30
AU2002214947B2 (en) 2007-02-15
KR100871577B1 (ko) 2008-12-02
IL155483A0 (en) 2003-11-23
CN100368401C (zh) 2008-02-13
CA2426601C (en) 2015-01-13
CZ305764B6 (cs) 2016-03-09
JP2004520282A (ja) 2004-07-08
RU2312858C2 (ru) 2007-12-20
HK1212678A1 (en) 2016-06-17
EP2894149B1 (en) 2017-08-02
WO2002042265A3 (en) 2002-08-15
EP1339686A2 (en) 2003-09-03
AU2002223511A1 (en) 2002-06-03
AU1494702A (en) 2002-06-03
HK1073297A1 (zh) 2005-09-30
HUP0400564A2 (hu) 2004-06-28
CZ20031303A3 (en) 2004-04-14
CN1589262A (zh) 2005-03-02
CA2426601A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
MXPA03004394A (es) Profarmacos de cianoguanidina.
CY1112201T1 (el) Φαρμακο για τη θεραπευτικη αγωγη γριπης
PH12022551661A1 (en) Mek inhibitors and therapeutic uses thereof
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
EA200100600A3 (ru) Новые соединения дифенилмочевины, способ их получения и содержащие их фармацевтические композиции
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
BR0002515A (pt) Derivados de 4-arilpiperidina para o tratamento do prurido
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
TW200635585A (en) Monocyclic substituted methanones
BRPI0518467A2 (pt) derivado de Ácido antranÍlico, inibidor de produÇço de metaloprotease de matriz 13, e, agente terapÊutico para artrite reumatàide
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
ATE452896T1 (de) C3-cyanoepothilonderivate
BRPI0813809A2 (pt) derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica.
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
BR112023018505A2 (pt) Compostos heterocíclicos de arila como bloqueadores de canais shaker kv1.3 de potássio
BR0312798A (pt) Derivados de isotiazol úteis como agentes anticancerìgenos
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]